Expertise en Vigilance Sanitaires : pharmacovigilance, cosmétovigilance, matériovigilance ... Fondée par Caroline NAVARRE en 1998, docteur en pharmacie et pharmacovigilant senior.
Dans le contexte toujours plus exigeant de la réglementation des produits de santé, VIGIPHARM est le partenaire de nombreux laboratoires pharmaceutiques pour l'élaboration de leur stratégie et l'exercice de la vigilance sanitaire, de manière globale ou partielle.
Rating Reviews
Rating is calculated based on
1
review and is evolving.
Pros: Work-life balance is pretty decent most of the time for CRAs. You can usually stick to 40-hour weeks if you're efficient with your clinical trial tasks. Being in the Paris office means I don't commute too far, which helps.
Cons: Some urgent regulatory affairs deadlines can make for really long days and weekends. It's tough to plan personal stuff during these periods. The hybrid model means you're still in the office a lot.
Advice to Management: Management really needs to look at project planning better to avoid those intense crunch times. It's hard on the team, especially for those of us handling multiple clinical trials. More support for regulatory affairs submissions would help a lot with balancing the workload.
Show more
What is the typical salary range for a pharmaceutical sales representative at VIGIPHARM in major US cities?
Salaries for pharmaceutical sales representatives at VIGIPHARM can vary based on experience and location, with positions in high-cost-of-living areas like New York or California often reflecting that. Entry-level roles might start around $60,000-$70,000, while experienced reps with a proven track record can earn upwards of $90,000-$110,000 base, plus commission and bonuses.
What is the typical work environment like at VIGIPHARM for pharmaceutical sales representatives in the Paris region?
The culture at VIGIPHARM fosters collaboration and a results-oriented approach. Sales teams often work autonomously but are supported by a strong management structure that encourages professional development within the competitive French pharmaceutical market.
FR
